Effect of Fuzheng Xiaowei Decoction on gastrointestinal motility and gastric mucosa repair in chronic atrophic gastritis rats induced by N-Methyl-N'-nitro-N-nitrosoguanidine

doi:10.3877/cma.j.issn.2095-8765.2023.01.003

Abstract

Abstract:

Objective

To study the effects of Fuzheng Xiaowei Decoction on gastrointestinal motility and gastric mucosal repair in chronic atrophic gastritis (CAG) rats induced by N-Methyl-N'-nitro-N-nitrosoguanidine(MNNG).

Methods

The rats were randomly divided into normal control group and modeling group, and the CAG rat model was established by MNNG combined with ethanol gavage. After modeling, the rats were randomly divided into model group, Fuzheng Xiaowei decoction low-dose, medium-dose and high-dose groups and enzyme group (10 rats per group). The low, medium and high dose groups of FuzhengXiaowei Decoction were given 0.74 g/kg, 1.48 g/kg and 2.22 g/kg by intragastric administration, respectively, and the vitase group was given 240 mg/kg intragastric administration of vitase, once a day for 6 w, and the gastric empting rate and small intestine propulsive ratio of rats were measured. The levels of gastrin (GAS), motilin (MTL) and somatostatin (SS) in rat serum and endothelin (ET), Prostaglandin E2 (PGE2), Secretory immunoglobulin A (sIgA) and glutathione (GSH) in rat gastric mucosa were determined by enzyme-linked immunosorbent assay (ELISA). The histopathological changes of gastric mucosa were detected by hematoxylin-eosin (HE) staining, and the apoptosis rate of gastric mucosal tissue was detected by Td-mediated dudpo-x nick end Labeling (TUNEL) staining. The protein levels of nuclear tran-scription factor 2 (Nrf2) and heme oxygenose 1 (HO-1) in gastric mucosa of rats were determined by Western blot.

Results

Compared with the normal control group, the levels of serum GAS, SS, gastric emptier rate, intestinal propulsion ratio, PGE2, sIgA, GSH levels, Nrf2 and HO-1 protein levels of gastric mucosa in model group were significantly decreased (P<0.05). Serum MTL level, ET level and apoptosis rate of gastric mucosa tissue were significantly increased (P<0.05). Compared with model group, the serum GAS, SS levels, gastric emptying rate, small intestine advancement ratio, PGE2, sIgA, GSH levels, Nrf2 and HO-1 protein levels of gastric mucosa in FuzhengXiaowei Decoction and vitase group were significantly increased (P<0.05). Serum MTL level, ET level in gastric mucosa tissue and apoptosis rate of gastric mucosa tissue were significantly decreased (P<0.05), and the above indexes were more significantly changed with the increase of the dose of FuzhengXiaowei Decoction.

Conclusion

Fuzheng Xiaowei Decoction can significantly regulate gastrointestinal hormone secretion, inhibit the apoptosis of gastric mucosa cells, promote the recovery of gastric motility, and repair the pathological changes of gastric mucosa in rats with chronic atrophic gastritis. The mechanism may be related to the regulation of Nrf2/HO-1 pathway.

Key words: Fuzheng Xiaowei Decoction, CAG rats, Gastrointestinal motility

Jinying Zhang, Yanjun Zhang. Effect of Fuzheng Xiaowei Decoction on gastrointestinal motility and gastric mucosa repair in chronic atrophic gastritis rats induced by N-Methyl-N'-nitro-N-nitrosoguanidine[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2023, 10(01): 11-17.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwsgflbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8765.2023.01.003

https://zhwsgflbdzzz.cma-cmc.com.cn/EN/Y2023/V10/I01/11

Figures/Tables 7

References 23

1	Holleczek B, Schöttker B, Brenner H. Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: results from the prospective population-based ESTHER cohort study[J]. Int J Cancer, 2020, 146(10): 2773-2783.
2	Liu S, Shu L, Yang J, et al. Rhein exhibits anti-inflammatory effects in chronic atrophic gastritis via Nrf2 and MAPK signaling[J]. Turk J Gastroenterol, 2023, 34(5): 525-532.
3	熊禹,李慧慧,王红梅. 扶正消萎汤辅助治疗脾胃虚弱型慢性萎缩性胃炎的临床效果[J]. 医学理论与实践, 2021, 34(22): 3912-3914.
4	李思汉,林秀明,田琳,等. 健脾清化舒络中药对慢性萎缩性胃炎大鼠Sonic Hedgehog信号通路的影响[J]. 北京中医药大学学报, 2021, 44(2): 143-151.
5	石铖,王茜,刘宇,等. 基于Keap1/Nrf2/ARE信号通路探讨半夏泻心汤对慢性萎缩性胃炎大鼠的影响及作用机制[J]. 中国实验方剂学杂志, 2021, 27(20): 31-37.
6	朱景茹,洪银洁,黄婉仪,等. 柴芍六君汤对肝郁脾虚型慢性萎缩性胃炎大鼠胃黏膜细胞增殖和凋亡因子的影响[J]. 中国比较医学杂志, 2021, 31(7): 9-14.
7	董利洋,孔慧,罗娟,等. 基于JAK2/STAT3信号通路探究半夏泻心汤对慢性萎缩性胃炎大鼠的影响[J]. 中医药导报, 2023, 29(3): 5-10.
8	黄婷婷,谢桂丹,蔡潇阳. 血清CD47水平与幽门螺杆菌感染及慢性萎缩性胃炎进展的关系[J]. 国际消化病杂志, 2022, 42(4): 237-242.
9	Zhang Y, Li F, Yuan F, et al. Diagnosing chronic atrophic gastritis by gastroscopy using artificial intelligence[J]. Dig Liver Dis, 2020, 52(5): 566-572.
10	时艳华,任喜尚,秦芳,等. 扶正消萎汤治疗脾胃虚弱型慢性萎缩性胃炎的临床观察[J]. 中华中医药学刊, 2020, 38(5): 86-88.
11	赵松峰. 扶正消萎汤治疗脾胃虚弱型慢性萎缩性胃炎的临床观察[J]. 中国社区医师, 2021, 37(4): 91-92.
12	李德增,柳瑞梅,李子英. 扶正消萎汤治疗脾胃虚弱型慢性萎缩性胃炎临床观察[J]. 光明中医, 2023, 38(10): 1836-1839.
13	黄铭涵,王文荣,黄健,等. 中药复方清化饮对慢性萎缩性胃炎大鼠血清IL-10、NO、GAS及血浆MTL的影响[J]. 西安交通大学学报(医学版), 2018, 39(1): 116-120.
14	吴丹娜,陈朝聪,余华军,等. 果胶铋联合磷酸铝凝胶对慢性萎缩性胃炎患者血清GAS ET IL-6 IL-12的影响[J]. 河北医学, 2021, 27(5): 869-873.
15	王春,陈丽康,陈梦梦,等. 自拟调胃汤对慢性萎缩性胃炎患者MTL和SS的影响[J]. 中药材, 2021, 44(11): 2707-2710.
16	赵晶凤,吴英,王秀艳,等. 养胃颗粒联合四联疗法治疗幽门螺杆菌阳性慢性萎缩性胃炎的疗效及对血清GAS、ET和PGs的影响[J]. 中国中西医结合消化杂志, 2018, 26(8): 640-644.
17	喻勤,彭昌能,刘浒. 复方丙谷胺西咪替丁对慢性萎缩性胃炎患者胃动力水平和胃黏膜PGE2水平的影响[J]. 实用药物与临床, 2021, 24(2): 138-142.
18	王富华,龙丹,钟冬水. 瑞巴派特治疗老年慢性萎缩性胃炎患者的疗效及对胃动力水平和胃黏膜PGE2水平的影响[J]. 医学理论与实践, 2021, 34(23): 4089-4091.
19	蒋时红,刘旺根,王雪萍,等. 黄芪建中汤对脾虚型慢性萎缩性胃炎大鼠胃肠道功能的影响[J]. 中药药理与临床, 2006, 22(3): 5-7.
20	田家豪,石悰悰,费素娟. 小檗碱通过抑制凋亡和炎症减轻大鼠慢性萎缩性胃炎病变的效果[J]. 世界中医药, 2023, 18(2): 200-205.
21	赵玲俊,列丽娜,王丽华,等. 血红素氧合酶1在慢性萎缩性胃炎的表达[J]. 临床荟萃, 2012, 27(6): 534-535.
22	陈英,曾强,徐鹏,等. 脊髓横断后艾灸足三里对胃黏膜损伤大鼠Nrf2/HO-1信号通路的影响[J]. 针灸临床杂志, 2022, 38(8): 38-45.
23	杜敏,李志民,霍伟. DC-CIK免疫治疗联合化疗对晚期胃癌的效果及对Nrf2、ARE蛋白表达水平的影响[J]. 临床和实验医学杂志, 2018, 17(15): 1627-1630.

组别	GAS	MTL	SS
正常对照组	1361.29±24.20	149.88±2.05	79.02±2.14
模型组	813.05±18.77^a	242.53±3.98^a	43.62±1.91^a
扶正消萎汤低剂量组	947.43±14.62^b	193.19±1.79^b	58.78±1.47^b
扶正消萎汤中剂量组	1183.71±26.46^bc	178.77±2.67^bc	65.05±1.82^bc
扶正消萎汤高剂量组	1289.54±26.34^bcd	155.80±3.58^bcd	74.71±1.39^bcd
维酶素组	1178.75±17.55	161.13±3.52	72.33±2.52

组别	GAS	MTL	SS
正常对照组	1361.29±24.20	149.88±2.05	79.02±2.14
模型组	813.05±18.77^a	242.53±3.98^a	43.62±1.91^a
扶正消萎汤低剂量组	947.43±14.62^b	193.19±1.79^b	58.78±1.47^b
扶正消萎汤中剂量组	1183.71±26.46^bc	178.77±2.67^bc	65.05±1.82^bc
扶正消萎汤高剂量组	1289.54±26.34^bcd	155.80±3.58^bcd	74.71±1.39^bcd
维酶素组	1178.75±17.55	161.13±3.52	72.33±2.52

组别	胃排空率	小肠推进比
正常对照组	81.23±3.64	63.14±2.25
模型组	53.04±1.57^a	40.09±1.64^a
扶正消萎汤低剂量组	62.26±1.17^b	49.21±1.92^b
扶正消萎汤中剂量组	70.84±2.96^bc	55.27±1.44^bc
扶正消萎汤高剂量组	78.29±3.36^bcd	60.78±1.26^bcd
维酶素组	75.20±1.20^b	57.26±1.55^b

组别	胃排空率	小肠推进比
正常对照组	81.23±3.64	63.14±2.25
模型组	53.04±1.57^a	40.09±1.64^a
扶正消萎汤低剂量组	62.26±1.17^b	49.21±1.92^b
扶正消萎汤中剂量组	70.84±2.96^bc	55.27±1.44^bc
扶正消萎汤高剂量组	78.29±3.36^bcd	60.78±1.26^bcd
维酶素组	75.20±1.20^b	57.26±1.55^b

组别	ET/(ng/L)	PGE2/(ng/L)	sIgA/(μg/ml)	GSH/(μmol/L)
正常对照组	240.19±2.71	83.96±2.24	63.44±3.77	64.89±2.94
模型组	389.71±3.69^a	37.14±1.89^a	20.23±3.78^a	8.23±1.36^a
扶正消萎汤低剂量组	318.07±3.41^b	51.29±1.93^b	35.07±2.47^b	38.45±2.70^b
扶正消萎汤中剂量组	264.72±1.58^bc	62.77±3.12^bc	48.66±3.31^bc	47.49±2.63^bc
扶正消萎汤高剂量组	248.06±2.28^bcd	79.11±2.13^bcd	57.07±4.69^bcd	58.97±2.60^bcd
维酶素组	253.61±2.63^b	73.54±2.67^b	55.23±1.58^b	55.33±1.69^b

Please choose a citation manager

Content to export